RxDoctor Payments Data

Lucia Sicinschi, MD

Internal Medicine · Covington, LANPI 1871773689

Payments from drug & device makers

$3,184in general payments, 2019–2025

Across 45 payments — averaging $70.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$533
  • Amgen$479
  • AstraZeneca$370
  • Johnson & Johnson$260
  • Pfizer$222
  • Lilly USA, LLC$186
  • plus $1K from 13 others

What the payments were for

  • Food & beverage$3,184100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,184 in reported general payments places this provider in the 80th percentile of 1,528 internal medicine providers in Louisiana.

See all internal medicine providers in Louisiana

Medicare billing

Part B allowed, 2024
$30,543
Medicare patients
143
Services billed
336

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin59$70,347
OzempicSemaglutide50$66,673
MounjaroTirzepatide39$50,068
EliquisApixaban31$25,236
TrulicityDulaglutide15$14,540
Lantus SolostarInsulin Glargine,hum.Rec.Anlog12$2,220
Levothyroxine Sodium90$1,072
Mirtazapine38$1,068
Rosuvastatin Calcium127$980
Ipratropium Bromide31$866
Atorvastatin Calcium110$854
Metoprolol Succinate66$842
Duloxetine Hcl59$832
Albuterol Sulfate HfaAlbuterol Sulfate40$756
Fluticasone Propionate55$745

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$533$66,67350 claims
Lilly USA, LLCMounjaro, Trulicity$186$64,60854 claims
PfizerEliquis$222$25,23631 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,528 internal medicine providers in Louisiana.

Other internal medicine in Covington

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →